Manufacturing methods to control C-terminal lysine, galactose and sialic acid content in recombinant proteins
US11149085B2 · kind B2 · utility
0Cited by
8References
33Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 23, 2015 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Dec 29, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein is a method for producing an antibody, such as an anti-TNFα antibody (e.g., infliximab) having a C-terminal lysine content of about 20% to about 70%, and a sialic acid content of about 1% to about 20%, comprising culturing a zinc-responsive host cell transfected with DNA encoding the antibody in a culture medium comprising at least 0.5 μM zinc; and controlling the concentration of zinc in the culture medium, thereby producing the antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.